FDA releases 14 drug rejection letters after 3-month pause

The FDA has resumed publishing drug rejection letters (Complete Response Letters) after a three-month pause, releasing 14 letters dating back to April 2026. The transparency initiative, championed by former FDA Commissioner Marty Makary, faces legal challenge from an unnamed pharma company seeking tighter redaction and sponsor involvement in disclosure. Your competitors' rejection letters are now public record—and they show exactly where clinical programmes fail and why. If you're in drug development, these CRLs are now free competitive intelligence; if you're selling solutions to pharma for CRL remediation, the market just got larger and more visible.